![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 12, 8041-8050, March 24, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||














1
From the
Vascular Biology Research Group, Robarts Research Laboratory, London, Ontario N6A 2K8, Canada, the
Department of Microbiology and Immunology, University of Western Ontario, London, Ontario N6A 2K8, Canada, ¶Research and Development, Viron Therapeutics, Inc., London, Ontario N6G 4X8, Canada, and the ||Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida 32610-0266
The thrombolytic serine protease cascade is intricately involved in activation of innate immune responses. The urokinase-type plasminogen activator and receptor form complexes that aid inflammatory cell invasion at sites of arterial injury. Plasminogen activator inhibitor-1 is a mammalian serpin that binds and regulates the urokinase receptor complex. Serp-1, a myxomaviral serpin, also targets the urokinase receptor, displaying profound anti-inflammatory and anti-atherogenic activity in a wide range of animal models. Serp-1 reactive center site mutations, mimicking known mammalian and viral serpins, were constructed in order to define sequences responsible for regulation of inflammation. Thrombosis, inflammation, and plaque growth were assessed after treatment with Serp-1, Serp-1 chimeras, plasminogen activator inhibitor-1, or unrelated viral serpins in plasminogen activator inhibitor or urokinase receptor-deficient mouse aortic transplants. Altering the P1-P1' Arg-Asn sequence compromised Serp-1 protease-inhibitory activity and anti-inflammatory activity in animal models; P1-P1' Ala-Ala mutants were inactive, P1 Met increased remodeling, and P1' Thr increased thrombosis. Substitution of Serp-1 P2P7 with Ala6 allowed for inhibition of urokinase but lost plasmin inhibition, unexpectedly inducing a diametrically opposed, proinflammatory response with mononuclear cell activation, thrombosis, and aneurysm formation (p < 0.03). Other serpins did not reproduce Serp-1 activity; plasminogen activator inhibitor-1 increased thrombosis (p < 0.0001), and unrelated viral serpin, CrmA, increased inflammation. Deficiency of urokinase receptor in mouse transplants blocked Serp-1 and chimera activity, in some cases increasing inflammation. In summary, 1) Serp-1 anti-inflammatory activity is highly dependent upon the reactive center loop sequence, and 2) plasmin inhibition is central to anti-inflammatory activity.
Received for publication, August 26, 2005 , and in revised form, October 27, 2005.
* This work was supported by the Heart and Stroke Foundation of Ontario, Canada Grant T5605 and the Canadian Institutes of Health Research Grant MOP 77578. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Robarts Research Institute, Vascular Biology Research Group, University of Western Ontario, 100 Perth Dr., P.O. Box 5015, London, Ontario N6A 2K8, Canada. Tel.: 519-685-8500 (ext. 34071); Fax: 519-663-3446; E-mail: arl{at}robarts.ca.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |